NCT05803915View on ClinicalTrials.gov

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

March 10, 2026

Conditions
Oral Squamous Cell Carcinoma
Interventions
DRUG

Toripalimab

The participants will receive Toripalimab 240mg intravenous infusion every 3 week, and Nimotuzumab 150mg/㎡ every 2 week for 2 cycles

Trial Locations (1)

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT05803915 - Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy | Biotech Hunter | Biotech Hunter